Table of Contents

01. NICE’s response to comments on the Appraisal Consultation Document (ACD

02. Consultee comments on the ACD - Gilead Sciences Ltd (idelalisib)

03. Consultee comments on the ACD - Chronic Lymphocytic Leukaemia Support Association

04. Consultee comments on the ACD - Royal College of Physicians

05. Commentator comments on the ACD - Novartis Pharmaceuticals (ofatumumab)

06. Clinical expert comments on the ACD – Fegan

07. Clinical expert comments on the ACD – Forconi

08. Public comments on the ACD received via the NICE website

09. Evidence Review Group response to company ACD comments